PRME — Prime Medicine Share News
0.000.00%
Last trade - 00:00- $676.54m
- $581.46m
- $4.63m
Brief: Prime Medicine Announces Strategic Restructuring To Focus On Opportunities In Large Genetic Liver Diseases, Cystic Fibrosis, And Partnered Programs Alongside CEO Leadership Transition
Brief: Prime Medicine Unveils Program For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)
U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot
Prime Medicine set for best day ever on Bristol Myers investment, licensing deal
U.S. STOCKS ON THE MOVE-CVS Health, Estee Lauder, NeuroBo Pharma
Prime Medicine rises after investment from Bristol Myers, licensing deal
U.S. RESEARCH ROUNDUP- Ally Financial, GE Vernova, Navient
U.S. STOCKS ON THE MOVE-Super Micro, Albemarle
U.S. STOCKS ON THE MOVE-Ginkgo, Jfrog, Alvotech
Prime Medicine drops after stock offering priced
Brief: Prime Medicine Announces Pricing Of Upsized Public Offering
Brief: Prime Medicine Receives Up To $15 Million From Cystic Fibrosis Foundation To Advance Hotspot And PASSIGE Prime Editors For Cystic Fibrosis
U.S. STOCKS ON THE MOVE-Halozyme, Scorpio Tankers
Prime Medicine falls after Stifel downgrades to 'hold', cuts PT
Brief: Prime Medicine And Myeloid Therapeutics Announce Settlement Of Pending Disputes
Brief: Prime Medicine, Inc. Q3 EPS USD -0.55
Brief: Prime Medicine Presents Prime Editing Data in Non-human Primates
BMO initiates Prime Medicine coverage with 'outperform'
Brief: Prime Medicine And Cimeio Therapeutics Announce Research Collaboration To Develop Prime Edited Shielded-Cell & Immunotherapy Pairs